These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32022788)

  • 41. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
    Rosenthal SH; Fenton ML; Harnett DS
    Gen Hosp Psychiatry; 1992 Jul; 14(4):285-6. PubMed ID: 1505751
    [No Abstract]   [Full Text] [Related]  

  • 42. Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
    Cabreira V; Soares-da-Silva P; Massano J
    Drugs; 2019 Apr; 79(6):593-608. PubMed ID: 30905034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
    Hauser RA; Hubble JP; Truong DD;
    Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
    Goetz CG; Tanner CM; Shannon KM; Carroll VS; Klawans HL; Carvey PM; Gilley D
    Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New drugs for Parkinson's disease.
    Hodges LC; Rapp CG
    J Neurosci Nurs; 1990 Aug; 22(4):254-7. PubMed ID: 2144560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
    Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
    Timofeeva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
    Ahlskog JE; Muenter MD; McManis PG; Bell GN; Bailey PA
    Mayo Clin Proc; 1988 Sep; 63(9):876-86. PubMed ID: 3045435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
    Klostermann F; Bojarski C; Marzinzik F; Maier A; Schindlbeck KA; Ehlen F
    Mov Disord; 2017 Feb; 32(2):300-301. PubMed ID: 27859611
    [No Abstract]   [Full Text] [Related]  

  • 52. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(2):73-6. PubMed ID: 16614538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
    Boiko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EY; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaitsev KA; Kostenko EV
    Neurosci Behav Physiol; 2008 Nov; 38(9):933-6. PubMed ID: 18975095
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
    Tao Y; Liang G
    Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
    Greig SL; McKeage K
    CNS Drugs; 2016 Jan; 30(1):79-90. PubMed ID: 26692288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
    Cedarbaum JM; Silvestri M; Clark M; Toy L; Harts A; Green-Parsons A; McDowell FH
    J Neural Transm Park Dis Dement Sect; 1990; 2(3):205-13. PubMed ID: 2257060
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
    Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
    BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.